Severe burn biotech MediWound sets terms for $75 million IPO
MediWound, a biotech developing treatments for severe burns and other hard-to-heal wounds, announced terms for its IPO on Monday. The Yavne, Israel-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, the company would command a fully diluted market value of $326 million. MediWound, which was founded in 2000, plans to list on the NASDAQ under the symbol MDWD. MediWound initially filed confidentially on December 23, 2013. Credit Suisse, Jefferies and BMO Capital Markets are the joint bookrunners on the deal.